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206Objective: Previous studies suggest that cytologic analysis of cells obtained by lavage of the pleural surfaces at
the time of resection of non–small cell lung cancer can identify patients at risk for recurrence. Because telome-
rase gene expression has been associated with worse outcome in non–small cell lung cancer, we hypothesized
that identification of cells obtained from pleural lavage that express telomerase would identify patients at risk for
recurrent disease.
Methods: Patients with presumed non–small cell lung cancer underwent thoracotomy with curative intent. Cells
obtained by lavage of the pleural surfaces were analyzed for telomerase catalytic subunit human telomerase re-
verse transcriptase mRNA expression using reverse transcriptase polymerase chain reaction.
Results: A total of 194 patients with stage I/II non–small cell lung cancer had adequate samples, and median
follow-up was 60 months (17-91 months). By using Cox models, no statistical differences were found between
human telomerase reverse transcriptase–negative and positive patients in disease-free survival (hazard ratio,
1.28; 95% confidence interval, 0.85-1.94; log-rank test, P ¼ .2349) or overall survival (hazard ratio, 1.13;
95% confidence interval, 0.72-1.79; log-rank test, P ¼ .5912)
Conclusions: Detection of human telomerase reverse transcriptase in cells obtained from pleural lavage of pa-
tients with stage I/II non–small cell lung cancer does not identify patients at risk for recurrent disease. (J Thorac
Cardiovasc Surg 2013;146:206-11)Local recurrences after surgical resection of stage I non–
small cell lung cancer (NSCLC) have been reported to be
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The Journal of Thoracic and Cardiovascular Surgmicrometastases are present at the time of resection in
a sizable portion of patients. Previous studies have
found that cytologic analysis of cells obtained by lavage
of the pleural surfaces at the time of surgical resection
of NSCLC can identify patients at higher risk for
recurrence.4,5 A recent meta-analysis of 31 studies from
22 centers found the detection of malignant cells in pleu-
ral lavage by cytologic analysis to be an independent pre-
dictor of worse NSCLC survival and recommended
upstaging such patients by one T category.5 However,
the overall rate of positive cytology in this analysis was
significantly less than the rate of recurrence, showing
that this technique failed to detect many patients in
whom recurrent disease would develop.
Cytologic analysis is now recognized as being less sen-
sitive and more subjective than some of the molecular
techniques now available to identify genes uniquely ex-
pressed by malignant cells. One gene showing particular
promise for improving identification of lung cancer cells
is telomerase, an enzyme that adds nucleotide repeats to
the end of chromosomes, thereby overcoming the normal
DNA shortening and cellular senescence.6,7 Maintaining
telomere length is a critical and perhaps a rate-limiting
step in the progression from dysplasia to cancer.6 Telome-
rase is not normally found in somatic human cells and hasery c July 2013
FIGURE 1. Reverse transcriptase polymerase chain reaction (RT-PCR)
analysis of human telomerase reverse transcriptase (hTERT) expression
in lavage specimens. The messenger RNA levels of hTERT were deter-
mined by using RT-PCR. Fragments were resolved on 2% agarose gels
and visualized by ethidium bromide staining. Lane 1 shows expression in
the positive control, a lung adenocarcinoma cell line, and lane 2 shows
the negative control, normal pleural mesothelial cells. Lanes 4-7 contain
pleural lavage specimens. MW, Molecular weight markers.
Abbreviations and Acronyms
CALGB ¼ Cancer and Leukemia Group B
CI ¼ confidence interval
DFS ¼ disease-free survival
hTERT ¼ human telomerase reverse transcriptase
NSCLC ¼ non–small cell lung cancer
OS ¼ overall survival
PCR ¼ polymerase chain reaction
RT-PCR ¼ reverse transcriptase polymerase chain
reaction
Boylan et al Evolving Technology/Basic Sciencebeen reported to be expressed in up to 93% of all
NSCLCs and 100% of small cell lung cancers.7 Further-
more, detection of telomerase in NSCLC tissues has
been associated with advanced stage and poorer survival,8
and has been shown to improve detection of NSCLC cells
in pleural effusions when combined with cytology.9 Be-
cause of the association of telomerase with malignant
transformation in lung cancer and its association with
worse outcome in NSCLC, we hypothesized that identifi-
cation of cells obtained from pleural lavage that express
telomerase would detect patients at risk for recurrent
disease.E
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SMATERIALS AND METHODS
Approval for the study was obtained from the institutional review board
for human research at each institution. After informed consent was ob-
tained, patients aged more than 18 years undergoing thoracotomy with cu-
rative intent for suspected or confirmed NSCLC were enrolled in Cancer
and Leukemia Group B (CALGB) 159902. At the time the chest was
opened, the visceral and parietal pleural surfaces were lavaged with 200
mL of normal saline solution. Pleural lavage liquid was collected in tubes
containing ethylenediaminetetraacetic acid and then shipped on ice to
a core laboratory for analysis. Total cellular RNA (average yield from
each sample 7.8  3.3 mg) was harvested from the cell pellet and reverse
transcribed into cDNA. The cDNA (2 mL) was used in hot-start polymerase
chain reaction (PCR) with primers based on the human telomerase
reverse transcriptase (hTERT) sequence: hTERT (forward, base pair
1790-1811) 50-AGTGTCTGGAGCAAGTTGCAAA-30 and hTERT
(reverse, base pair 1970-1987) 50-CGTTCTGGCTCCCACGAC-30 (limit
of detection: 50 malignant cells/2000 normal cells by spiking cell suspen-
sions with tumor cells). The amplified fragments were separated in 2%
agarose gels and visualized by ethidium bromide staining. As control for
RNA integrity and reverse transcription, rRNA levels in each sample
were determined by amplifying equal amounts of cDNA (1 mL) using the
following primers: forward 50-CTCCGGTCCGTGCCTCCAAG-30 and re-
verse 50-CAGAGAATAGCCTGTCTTCAGTC-30. Reverse transcriptase
polymerase chain reaction (RT-PCR) assays were determined indepen-
dently as positive or negative by 2 investigators blinded to the clinical
and histopathologic information (Figure 1). The limit of detection for
this assay was determined to be 50 malignant cells/2000 normal cells by
spiking cell suspensions with tumor cells. Telomerase activity was found
in the following positive controls: a pancreatic cancer cell line and 2 malig-
nant effusions caused by metastatic adenocarcinoma of the lung. No telo-
merase activity was found in the following negative controls: cells from
a transudative effusion and cells from normal lung. The laboratory leadThe Journal of Thoracic and Caby the first author processed the specimens. Assays were conducted with-
out knowledge of clinical outcomes.
Statistical Methods
The study was designed to enroll a total of 180 patients with stage I or
II NSCLC who underwent complete resection. The sample size was justi-
fied with the assumption that 20% of these patients would have positive
test results. With 102 failures observed from the 180 patients, the study
has 80% power at 2-sided significance level of .05 to detect a 2-fold in-
crease in the risk of disease recurrence (hazard ratio, 2.0) for marker pos-
itives over marker negatives, that is, a decrease of 2-year disease-free
survival (DFS) rate from 60% for marker negatives to 36% for marker
positives. Patient registration and clinical data collection were managed
by the CALGB Statistical Center. Clinical data quality was ensured by
careful review of data by the CALGB Statistical Center staff and by the
study chair. The statistical analyses were performed by CALGB statisti-
cians using SAS 9.1 (SAS Institute Inc, Cary, NC). The association of de-
mographic and clinical variables with telomerase activity (presence or
absence of hTERT in cells) was tested using chi-square tests for categoric
variables and Wilcoxon rank-sum tests for continuous variables. Kaplan–
Meier curves were used to characterize survival for patients with and with-
out telomerase. The median survival times and the corresponding 95%
confidence intervals (CIs) were computed for overall survival (OS) and
DFS. OS was defined as the time from patient registration to death from
any cause. DFS was defined as time from patient registration to disease
recurrence or death, whichever comes first. The log-rank test was used
to compare survival between patient subgroups. Cox proportional hazards
model was used to examine the effect of the presence of telomerase on
DFS and OS without or with adjustment for other baseline prognostic fac-
tors. All P values reported are 2 sided.
RESULTS
Of the 364 patients accrued (from October 26, 2000, to
September 30, 2003), 30 had benign disease, 43 had stage
III or IV disease, and 13 had other types of cancer. Samples
from 62 patients could not be analyzed because of shipping
errors, such as frozen samples, leakage of specimens, loss of
shipment, or delays in shipment leading to specimens arriv-
ing at room temperature. Two patients withdrew from the
study, and the diagnosis was uncertain in 9 patients. Of
the patients confirmed to have NSCLC, 194 had stage I/II
with adequate samples for analysis (64 presentedrdiovascular Surgery c Volume 146, Number 1 207
TABLE 1. Patient demographic and baseline clinical characteristics
Characteristics
Telomerase activity N (%)
Total
(N ¼ 194)
Absent
(N ¼ 130)
Present
(N ¼ 64)
Age median (min, max) 67 (39, 86) 70 (52, 85) 68 (39, 86)*
Race
White 123 (69.5) 54 (30.5) 177y
Nonwhite 5 (35.7) 9 (64.3) 14
Unknown 2 (66.7) 1 (33.3) 3
Gender
Male 67 (68.4) 31 (31.6) 98
Female 63 (65.6) 33 (34.4) 96
ECOG PS
0 65 (64.4) 36 (35.6) 101
1, 2 58 (72.5) 22 (27.5) 80
Unknown 7 (53.8) 6 (46.2) 13
Histology
Adenocarcinoma 64 (68.1) 30 (31.9) 94
Other types 66 (66.0) 34 (34.0) 100
Stage
I 111 (69.4) 49 (30.6) 160
II 19 (55.9) 15 (44.1) 34
ECOG, Eastern Cooperative Oncology Group; PS, performance status. *Two-sided
P value for age (.082) was from Wilcoxon rank-sum test. yTwo-sided P value for
race (.016) was from Fisher exact test.
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Stelomerase activity, 79 deaths, and 96 deaths or relapse). On
histologic analysis, 48.5% of cases were adenocarcinomas,
39.7% were squamous cell carcinomas, 4.1% were large
cell carcinomas, 4.1% were bronchoalveolar cell carcino-
mas, and 3.6% were poorly differentiated carcinomas.
The median follow-up time was 60 months (5 years) (range,
17-91 months).
Telomerase activity was not statistically associated
with gender, performance status, histology, and stage
(P> .10) (Table 1). However, white patients tended to
have a higher proportion (69%) of telomerase absence
than the rest of the patients (41%) (Fisher exact test,
P ¼ .016), and patients with telomerase absence tended
to be younger (median age, 67 years) compared with pa-
tients with telomerase present (median age, 70 years)
(Wilcoxon rank-sum test, P ¼ .082). Of 30 samples
from patients with benign disease, 22 were tested for tel-
omerase activity, and of these, 4 were found to be posi-
tive (18%).TABLE 2. Kaplan–Meier product limit estimates of overall survival and d
Telomerase activity Patients (n) Events (n) Median survival (y
OS
Absent 130 50 NA (5.6, N
Present 64 29 5.9 (4.1, N
DFS
Absent 130 59 5.8 (4.4, N
Present 64 37 4.2 (2.4, 5
CI, Confidence interval; OS, overall survival; DFS, disease-free survival; NA, not availabl
208 The Journal of Thoracic and Cardiovascular SurgOS and DFS were estimated by the Kaplan–Meier
method (Table 2 and Figure 2). The estimates of 5-year
survival were calculated along with their 95% CI. The
5-year OS was 62.2% (95% CI, 52.8-70.2) for patients
with telomerase absence and 55% (95% CI, 40.7-67.1)
for patients with telomerase present (log-rank P ¼ .59).
The 5-year DFS was 58.1% (95% CI, 48.8-66.2) for pa-
tients with telomerase absence and 44.1% (95% CI,
31.0-56.4) for patients with telomerase present (log-rank
P ¼ .23). The Cox univariate model (model 1) and multi-
variate model (model 2) were fit to assess the effect of tel-
omerase on OS and DFS, respectively. In the multivariate
model, covariates of age, race, gender, Eastern Coopera-
tive Oncology Group performance status, histology, and
stage were adjusted for. As shown in Table 3, no statisti-
cally significant difference in terms of OS and DFS be-
tween patients with and without telomerase was present,
whereas female patients (performance status ¼ 0) and pa-
tients with stage I had more favorable survivals than their
counterparts (P < .06) according to the multivariate
analysis.DISCUSSION
The primary objective of this study was to examine the
relationship between telomerase activity (hTERT) in
pleural lavage fluids and survival among patients with
pathologic stage I and II NSCLC undergoing surgical re-
section with curative intent. The results suggest that de-
tecting telomerase in cells obtained by lavage of the
pleura is not associated with worse DFS or OS in these
patients.
Although the specificity of telomerase activity for detect-
ing NSCLC is reportedly high (85.7% in bronchial lavage
specimens),10 the false-positive rate for samples taken
from the lungs of patients with suspected NSCLC has
been reported to be 10% to 14.7%.10 In all cases, the
false-positives were associated with inflammatory pro-
cesses, perhaps reflecting the presence of activated lympho-
cytes that have been shown to be capable of expressing
telomerase.11 Such activated lymphocytes might have
been a confounding variable in our study.
The sensitivity and specificity of measument of telome-
rase activity for detection of malignant cells also varyisease-free survival by telomerase activity
) (95% CI) 5-y Survival (%) (95% CI) Log-rank test P value
A) 62.2 (52.8-70.2) .59
A) 55.0 (40.7-67.1)
A) 58.1 (48.8-66.2) .23
.9) 44.1 (31.0-56.4)
e.
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FIGURE 2. Kaplan-Meier curves of (A) disease-free survival and (B) overall survival by telomerase activity.
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Sdepending on the technique used, and there is some re-
search to suggest analysis for proteins involved in teleomer-
ase activation is superior to measurements of enzymatic
activity. One such protein is hTERT. This protein is
a rate-limiting determinant of the enzymatic activity of hu-
man telomerase.12 Its expression seems to develop early in
tumorigenesis13 and is associated with shorter survival in
NSCLC.14 Because of these factors, the ability to use
more sensitive PCR technology to detect low numbers of
malignant cells and the evidence suggesting that hTERT
may be a more specific marker of cancer cells,15 we choseThe Journal of Thoracic and Cato analyze our specimens using RT-PCR to detect
expression of hTERT.
Strengths of our study include the fact that it was
a prospective, protocol-driven study with multiple centers
involved. Patients were prospectively followed for a median
of 5 years, and outcome data were correlated with molecu-
lar analysis and pathologic stage. Study limitations include
a relatively low sample size because of higher than
expected numbers of patients with higher stage disease,
benign or other cancers, loss of samples due to shipping
errors, and a high false-positive rate. Also, RT-PCR wasrdiovascular Surgery c Volume 146, Number 1 209
TABLE 3. Relationship between telomerase activity and overall survival/disease-free survival from Cox proportional hazard model without
(model 1) and with (model 2) adjustments for other prognostic factors
Overall survival Disease-free survival
HR 95% CI P value HR 95% CI P value
Model 1*
Telomerase present vs absent 1.13 0.72-1.79 .59 1.28 0.85-1.94 .24
Model 2y
Telomerase present vs absent 1.06 0.64-1.76 .82 1.26 0.80-1.98 .32
Age (change by 1-y) 1.02 0.99-1.05 .24 1.02 0.99-1.04 .24
White vs nonwhite 0.77 0.34-1.74 .53 0.74 0.35-1.56 .43
Male vs female 1.91 1.17-3.14 .01 1.71 1.10-2.65 .018
PS ¼ 0 vs 1/2 0.60 0.37-0.97 .037 0.65 0.42-1.02 .059
Adeno vs others 1.06 0.65-1.72 .82 1.23 0.79-1.90 .35
Stage I vs II 0.54 0.32-0.92 .022 0.57 0.35-0.94 .027
HR, Hazard ratio; CI, confidence interval; PS, performance status; Adeno, adenocarcinoma. *Univariate model without any covariates. yMultivariate model adjusting for age,
race, gender, Eastern Cooperative Oncology Group performance status, histology type, and stage.
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Sused, which is less sensitive than currently available quan-
titative PCR.
CONCLUSIONS
The use of a PCR-basedmethod to detect telomerase gene
expression in cells obtained by pleural lavage of patients
with stage I or II NSCLC failed to identify patients at risk
for recurrence. It may be that the number of malignant cells
in the pleural space is too few for even a sensitive method of
detection such as PCR. Given the high false-positive rate in
benign inflammatory lesions, it may also be that differenti-
ation of patients with higher risk of recurrence requires the
association of telomerase activity with the presence of reac-
tive lymphocytes or other molecular markers of malignancy
to improve prognostic differentiation.
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